Translational Simoa Sensitivity Blood-Based Biomarkers for Neurological Drug Development & Clinical Trial Support
Time: 1:45 pm
day: Conference Day One
Details:
- New high-sensitivity blood-based assays for optimal detection of a wide range of neurodegeneration conditions
- Specific examples of clinical trial utility of Simoa biomarkers for NfL, N4PE, GFAP, and pTau 181 and pTau217
- The translational impact of blood-based biomarkers with Simoa sensitivity for Multiple Sclerosis, and Alzheimer's Disease detection and monitoring
